Edition:
United Kingdom

Pharmaceuticals

Page 1

Luye Pharma Group Now Pursuing Acquisition Of 98.0% Of Stake In Shandong Boan

2:30pm GMT

Feb 17 (Reuters) - Luye Pharma Group Ltd <2186.HK>::NOW PURSUING ACQUISITION OF 98.0% OF EQUITY INTEREST IN SHANDONG BOAN.

Livzon Pharmaceutical Group Says NMPA Accepts Registration Of Drug

2:29pm GMT

Feb 17 (Reuters) - Livzon Pharmaceutical Group Inc <000513.SZ>::NMPA ACCEPTS REGISTRATION OF OCTREOTIDE ACETATE MICROSPHERES FOR INJECTION BY UNITS.

India's Orchid Pharma Dec-Quarter Loss Widens From Sept-Quarter

1:53pm GMT

Feb 17 (Reuters) - Orchid Pharma Ltd ::DEC-QUARTER LOSS 276.9 MILLION RUPEES VERSUS LOSS OF 260.7 MILLION RUPEES LAST QUARTER.DEC-QUARTER INCOME FROM OPERATIONS 1.29 BILLION RUPEES VERSUS 1.32 BILLION RUPEES LAST QUARTER.

Veloxis Pharmaceuticals Elects Chairman

11:11am GMT

Feb 17 (Reuters) - Veloxis Pharmaceuticals AS ::BOARD OF DIRECTORS HAS CONSTITUTED ITSELF WITH MASAYA ETOH AS CHAIRMAN.

Essex Bio-Technology Updates On Potential Impact Of Novel Coronavirus On Business Operations

9:44am GMT

Feb 17 (Reuters) - Essex Bio-Technology Ltd <1061.HK>::UPDATES ON POTENTIAL IMPACT OF NOVEL CORONAVIRUS ON BUSINESS OPERATIONS.IF MEASURES IN PRC ARE NOT LIFTED SOON, CO'S TURNOVER AND RESULTS IN IMMEDIATE MONTHS WOULD BE NEGATIVELY IMPACTED.

Boya Bio-Pharmaceutical's Trading In Shares To Halt Pending Regulatory Review Of Asset Acquisition

8:52am GMT

Feb 17 (Reuters) - Boya Bio-pharmaceutical Group Co Ltd <300294.SZ>::SAYS TRADING IN SHARES TO HALT FROM FEB 18 PENDING REGULATORY REVIEW OF ITS ASSET ACQUISITION.

Vifor Pharma Agreed To Purchase FDA Priority Review Voucher

6:00am GMT

Feb 17 (Reuters) - VIFOR PHARMA AG ::VIFOR PHARMA ACQUIRES PRIORITY REVIEW VOUCHER.IT HAS AGREED TO PURCHASE A US FOOD AND DRUG ADMINISTRATION (FDA) PRIORITY REVIEW VOUCHER (PRV).

Corrected-Zhejiang Hisun Pharma gets approval for clinical trial to test flu drug Favipiravir for pneumonia caused by new coronavirus

1:11am GMT

Corrects headline and bullets to show company gets approval for clinical trial to test Favipiravir for pneumonia caused by novel coronavirus:RECEIVES APPROVAL TO MANUFACTURE FAVIPIRAVIR FOR NEW AND RECURRING INFLUENZA IN ADULTS.SAYS IT RECEIVES APPROVAL TO START CLINICAL TRIALS FOR USE OF FAVIPIRAVIR TO TREAT PNEUMONIA CAUSED BY NEW CORONAVIRUS.

Markets

  • Sectors
  • Europe
  • U.S.
  • Asia

Sector Summary